Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

US7910703B2 · kind B2 · utility

Assignee

• ZYMOGENETICS INC. · US

Inventors

• Katherine E. Lewis · Lake Forest Park, US
• Scott R. Presnell · Tacoma, US
• Steven D. Levin · Seattle, US
• George Robert Mabry, III · Needham, US
• Stephen R. Jaspers · Edmonds, US
• Monica J. Huber · Bothell, US

Key dates

• Filing date: Apr 28, 2008
• Grant date: Mar 22, 2011
• Expiry date: Apr 28, 2028

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/809
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.